(CercleFinance.com) – Roche today presented new two-year data from two studies looking at Vabysmo (faricimab) as a treatment for age-related macular degeneration (AMD), a disease that affects nearly 20 million people worldwide and may require treatment with eye injections every one to two months.
The data demonstrates the efficacy, safety and long-term durability of the treatment.
“These longer-term results build confidence in Vabysmo and support its continued use in people with neovascular AMD,” said Levi Garraway, Chief Medical Officer and Head of Global Product Development at Roche.
He adds that these data ‘represent an important step forward for people with vision-threatening retinal diseases’ and demonstrate Roche’s commitment to redefining the standards of care and reducing the burden of treatment for people with AMD.
The two-year data was presented today at the 2022 Annual Scientific Meeting of the American Society of Retina Specialists.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
